Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Total Liabilities (2016 - 2025)

Bioceres Crop Solutions' Total Liabilities history spans 9 years, with the latest figure at $468.4 million for Q2 2025.

  • For Q2 2025, Total Liabilities fell 6.53% year-over-year to $468.4 million; the TTM value through Jun 2025 reached $468.4 million, down 6.53%, while the annual FY2025 figure was $468.4 million, 6.53% down from the prior year.
  • Total Liabilities for Q2 2025 was $468.4 million at Bioceres Crop Solutions, down from $501.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $501.2 million in Q2 2024 and bottomed at $57.4 million in Q4 2021.
  • The 5-year median for Total Liabilities is $414.2 million (2022), against an average of $363.1 million.
  • The largest annual shift saw Total Liabilities surged 35.46% in 2023 before it decreased 6.53% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $57.4 million in 2021, then surged by 527.01% to $359.9 million in 2022, then soared by 35.46% to $487.6 million in 2023, then grew by 2.79% to $501.2 million in 2024, then fell by 6.53% to $468.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIOX's Total Liabilities are $468.4 million (Q2 2025), $501.2 million (Q2 2024), and $487.6 million (Q2 2023).